Discovery of GPCR Agonist Antibodies Using the FAST Platform
9:30 am - Thursday 4th March 2027
- Abalone Bio’s Functional Antibody Selection Technology (FAST) platform measures antibody activity at scale, not just binding, enabling the discovery and design of agonist antibodies for GPCRs
- The large-scale sequence-function datasets generated uniquely power AI/ML models to identify novel active antibody sequences
- Using FAST, we have identified diverse agonists against five GPCRs, 3/3 with in vivo activity
